Xenetic biosciences, inc. announces signing of patent assignment related to collaboration with volitionrx limited and cls therapeutics

Signing of patent assignment from cls therapeutics as part of a collaboration agreement with volition and cls therapeutics to develop nets-targeted adoptive cell therapies for the treatment of cancer framingham, ma / accesswire / october 11, 2022 / xenetic biosciences, inc. (nasdaq:xbio) ("xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from cls therapeutics, inc. ("cls") to xenetic related to xenetic's previously announced collaboration with volitionrx limited (nyse american:vnrx) ("volition"), a multi-national epigenetics company, and cls, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. in consideration of the patent assignment, xenetic will also issue 850,000 shares of common stock to cls.
VNRX Ratings Summary
VNRX Quant Ranking